Drug Approval | March 22, 2025
SMS Pharmaceuticals completes USFDA inspection at Hyderabad facility
The inspection, conducted from March 17 to March 21, 2025, concluded with one observation in Form 483
The inspection, conducted from March 17 to March 21, 2025, concluded with one observation in Form 483
Through strong industry cooperation, significant investment, and smart policy backing, API manufacturing may become self-reliant
This expanded partnership helps Evonik to streamline its distribution model in Asia Pacific
Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD
Havix was incorporated under the laws of the State of Delaware on February 17, 2015
Will add UNLOXCYT (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) to Sun Pharma's global onco-derm franchise
USFDA inspection at Alembic Pharma's Bioequivalence facility
This achievement underscores the company’s steadfast commitment to sustainability, corporate responsibility, and ESG excellence
Carson brings with him over two decades of experience in Communications, Public Affairs, and Sustainability
The basket acquired, comprises of 13 ANDAs, which are approved by the USFDA and 1 ANDA, which is pending approval from the USFDA
Subscribe To Our Newsletter & Stay Updated
